SI
AMLX icon

Sofinnova Investments’s Amylyx Pharmaceuticals AMLX Stock Holding History

Sofinnova Investments’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-300,000
Closed -$570K – 66
2024
Q2 		$570K Hold
300,000
– – 0.03% 74
2024
Q1 		$852K Buy
+300,000
New +$3.92M 0.05% 63

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Sofinnova Investments's AMLX Position: Q1 2026 in Review

Sofinnova Investments sold out of Amylyx Pharmaceuticals (AMLX) in Q1 2026, closing a stake of 527,099 shares — an estimated $6.37M sold.

Sofinnova Investments first reported a position in AMLX in Q1 2022 and held it in 5 quarters. The position peaked at $6.37M in Q4 2025. 171 funds tracked by Wall St. Rank hold AMLX as of Q1 2026.

  • Sofinnova Investments reported no remaining Amylyx Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Sofinnova Investments sold 527,099 Amylyx Pharmaceuticals shares in Q1 2026, an estimated $6.37M.
  • Sofinnova Investments first reported a position in Amylyx Pharmaceuticals in Q1 2022 and held it in 5 quarters.
  • Sofinnova Investments's Amylyx Pharmaceuticals position peaked at $6.37M in Q4 2025.
  • 171 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2026.

Based on Sofinnova Investments's 13F filing for Q1 2026, filed 15 May 2026.